For many individuals, IV therapy is one of the most efficient ways to support optimal glutathione levels
N.BonomoR
Another commenter stated that, per the criteria described at 419.66(c), CMS has previously established this device category in the CY 2023 OPPS/ASC final rule with comment period
We used an inflation factor of 1.05440 to estimate CY 2025 charges from the CY 2024 charges reported on CY 2024 claims before applying CY 2025 CCRs to estimate the percent of outliers paid in CY 2025
10.3389/fendo.2018.00802 Summary Keywords hepatocytes, hepatocyte-like cells, induced pluripotent stem cells, growth factors, small molecules Citation Asumda FZ, Alzoubi S, Padarath K, Jones K, Kolhe R, Mondal AK, Alptekin A, Zhi W, Lee TJ, Huebert RC, Staff NP, Roberts LR and Kirkeby LA (2025) Comparative analysis of small molecule and growth factor-derived human induced pluripotent stem cell-derived hepatocyte-like cells